First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations.
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 08 Jun 2016 Status changed from active, no longer recruiting to completed, as per results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 08 Jun 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research